Kura Oncology director granted 35,000 stock options

Kura Oncology director Helen Louise Collins received a new stock option grant that increases her potential equity stake in the company.

Rhea-AI Filing Summary

Kura Oncology director Helen Louise Collins received a new stock option grant that increases her potential equity stake in the company. She was awarded options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. The options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this grant, she holds options covering 35,000 shares directly.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider Collins Helen Louise

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	35,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 35,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests in full on the one year anniversary of the date of grant.

Key Figures

Option grant size: 35,000 options Exercise price: $8.77 per share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 35,000 options Options to purchase common stock granted to director

Exercise price $8.77 per share Strike price for newly granted options

Expiration date June 3, 2036 Option grant expiration

Underlying shares 35,000 shares Common stock underlying the options

Post-grant option holdings 35,000 options Total derivative shares following transaction

Key Terms

Option to purchase common stock, grant/award acquisition, exercise price, expiration date, +1 more

5 terms

Option to purchase common stock financial

"security_title: Option to purchase common stock"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 8.7700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests in full financial

"This option vests in full on the one year anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kura Oncology (KURA) report for Helen Louise Collins?

Kura Oncology reported that director Helen Louise Collins received options to purchase 35,000 shares of common stock. The grant was recorded as a compensation-related award, not an open-market purchase or sale of existing shares.

What is the exercise price of the new Kura Oncology (KURA) stock options?

The newly granted options to Helen Louise Collins have an exercise price of $8.77 per share. This is the price she must pay per share to convert the options into common stock once they are vested and exercised.

When do Helen Louise Collins’s Kura Oncology (KURA) options vest?

The options granted to Helen Louise Collins vest in full on the one-year anniversary of the grant date. She must wait until that vesting date before exercising the options to acquire Kura Oncology common shares.

When do the newly granted Kura Oncology (KURA) options expire?

The stock options granted to Helen Louise Collins expire on June 3, 2036. If not exercised by that expiration date, the options will lapse and no longer allow her to purchase Kura Oncology common stock.

How many Kura Oncology (KURA) shares are covered by Helen Louise Collins’s new options?

The grant covers options for 35,000 underlying shares of Kura Oncology common stock. After this award, her directly held option position reflected in the filing totals 35,000 shares linked to this option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$8.77	06/04/2026		A		35,000		(1)	06/03/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

	/s/ Teresa Bair, Attorney-in-fact for Helen Collins	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)